So 2024 VarSome-vs-CanVIG-UK agreement on conflicting BRCA1 missense variants
Each of 450 conflicting BRCA1 missense ClinVar variants independently classified by VarSome and by the CanVIG-UK gene-specific guidance, each consolidated to a three-category scheme (PV/LPV, VUS, BV/LBV); overall concordance measured across the matched pairs.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
1 recorded evaluation, 2 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
1 evaluation · 2 results. Different protocols are not a single leaderboard.
Protocol: So 2024 VarSome-vs-CanVIG-UK agreement on conflicting BRCA1 missense variants · Dataset: So 2024 BRCA1 conflicting-classification missense cohort
Sorted by Percent agreement (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Percent agreement | Count (concordant classifications) |
|---|---|---|
| VarSome vs. CanVIG-UK three-category concordance comparisonEvaluation | 58.9% | 265 |
All 2 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: VarSome vs. CanVIG-UK three-category concordance comparison | Protocol: So 2024 VarSome-vs-CanVIG-UK agreement on conflicting BRCA1 missense variants Dataset: So 2024 BRCA1 conflicting-classification missense cohort | 58.9% Percent agreement percent · higher Uncertainty: 95% CI 52.0 to 66.4 Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceSo 2024 VarSome-vs-CanVIG-UK agreement evaluation Not reported Aggregation: Not reported Reinterpretation of Conflicting ClinVar BRCA1 Missense Variants Using VarSome and CanVIG-UK Gene-Specific Guidance · Results, Section 3.3, "Comparison of Classification Results Between Varsome and CanVIG-UK": "The overall concordance rate was 58.9% (95% CI: 52.0-66.4%; 265/450) between VarSome and CanVIG-UK (Figure 2)." |
| Configuration: VarSome vs. CanVIG-UK three-category concordance comparison | Protocol: So 2024 VarSome-vs-CanVIG-UK agreement on conflicting BRCA1 missense variants Dataset: So 2024 BRCA1 conflicting-classification missense cohort | 265 Count (concordant classifications) count · unknown Uncertainty: Not applicable: reported at the rate level only; see concordance_rate result Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceSo 2024 VarSome-vs-CanVIG-UK agreement evaluation Not reported Aggregation: Not reported Reinterpretation of Conflicting ClinVar BRCA1 Missense Variants Using VarSome and CanVIG-UK Gene-Specific Guidance · Results, Section 3.3, "Comparison of Classification Results Between Varsome and CanVIG-UK": "The overall concordance rate was 58.9% (95% CI: 52.0-66.4%; 265/450) between VarSome and CanVIG-UK (Figure 2)." |
Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Evaluation design
Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.
These source-backed links do not make different protocols or scores interchangeable.
Recorded evaluations
Each evaluation records what was tested and under which conditions.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 1
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Training-set class prior where supervised fitting is permitted
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Regularised classifier on simple permitted features, or protocol's conventional reference
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-21-adc15377fab2. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
1 evidence row matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Relationship: part of uc-clinical-20261005-so-2024-benchmark Individual claims | Reinterpretation of Conflicting ClinVar BRCA1 Missense Variants Using VarSome and CanVIG-UK Gene-Specific Guidance Results, Section 3.3, "Comparison of Classification Results Between Varsome and CanVIG-UK" Version: 2024 published article (Diagnostics (Basel)); CanVIG-UK gene-specific guidance v1.17 / consensus specification v2.17 applied | source checked ["automated-source-review"] · 2026-10-05 Audit detailsTranscription from inspected primary source. No execution, independent replication or human scientific review. Field: Claim: uc-clinical-20261005-so-2024-membership Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-adc15377fab2 · Record review: source checked
1 source record and release history
- Reinterpretation of Conflicting ClinVar BRCA1 Missense Variants Using VarSome and CanVIG-UK Gene-Specific Guidance · Original source · 2024 published article (Diagnostics (Basel)); CanVIG-UK gene-specific guidance v1.17 / consensus specification v2.17 applied
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID uc-clinical-20261005-so-2024-protocol.